Emanual Maverakis, MD
Dermatology · Sacramento, CANPI 1942274592
Payments from drug & device makers
Across 529 payments — averaging $6609.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.9M
- Eli Lilly$667K
- Novartis$322K
- Amgen$205K
- Hoffmann-la Roche Limited$164K
- Sanofi US Services Inc.$109K
- plus $156K from 18 others
Across 8 payments — averaging $1095.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8K
- F. Hoffmann-la Roche AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 284 | $1,873,640 |
| Eli Lilly | 44 | $666,907 |
| Novartis | 21 | $321,722 |
| Amgen | 13 | $204,901 |
| Hoffmann-la Roche Limited | 10 | $163,578 |
| Sanofi US Services Inc. | 16 | $109,446 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $107,248 |
| Pfizer | 6 | $12,841 |
| E.r. Squibb & Sons, L.L.C. | 25 | $11,451 |
| Argenx US, Inc. | 10 | $9,762 |
| Sanofi | 15 | $4,322 |
| Kyowa Kirin Co., Ltd | 7 | $4,157 |
| F. Hoffmann-la Roche AG | 3 | $2,113 |
| LEO Pharma AS | 1 | $1,810 |
| Incyte Corporation | 22 | $934 |
| Galderma Laboratories, L.p. | 5 | $423 |
| Sun Pharmaceutical Industries Inc. | 9 | $318 |
| LEO Pharma Inc. | 3 | $278 |
| Regeneron | 5 | $247 |
| Regeneron Healthcare Solutions, Inc. | 1 | $111 |
| Janssen Scientific Affairs, LLC | 2 | $46 |
| Tactile Systems Technology Inc | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$3,496,306 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Sacramento
- Raja SivamaniSacramento$11.8M
- Jennifer OrnelasSacramento$1.3M
- Emil TanghettiSacramento$1.2M
- Stephanie leSacramento$1.1M
- Vivian LaquerIrvine$20.9M
- Howard SofenLos Angeles$16.1M
- Jennifer SoungSanta Ana$10.3M
- Stacy SmithEncinitas$7.9M
- Paul YamauchiSanta Monica$7.8M
- Navid EzraThousand Oaks$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.